{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Keller MD"],"funding":["California Institute for Regenerative Medicine","California Institute for Regenerative Medicine (CIRM)"],"pagination":["2749"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10980733"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare adverse events have been described. Here we describe a unique and severe adverse event of VST therapy in an infant with severe combined immunodeficiency, who receives, as part of a clinical trial (NCT03475212), third party VSTs for treating cytomegalovirus viremia following bone marrow transplantation. At one-month post-VST infusion, rejection of graft and reversal of chimerism is observed, as is an expansion of T cells exclusively from the VST donor. Single-cell gene expression and T cell receptor profiling demonstrate a narrow repertoire of predominantly activated CD4<sup>+</sup>"],"journal":["Nature communications"],"pubmed_title":["Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication."],"pmcid":["PMC10980733"],"funding_grant_id":["CLIN2-10392"],"pubmed_authors":["Pulsipher MA","Qayed M","Keller MD","Pai SY","Parikh S","Chandrakasan S","Allen EK","Jensen-Wachspress MA","Schattgen SA","Gottschalk S","Lang H","Tanna J","Bollard CM","Berger SI","Lazarski CA","Thomas PG","Hanley PJ"],"additional_accession":[]},"is_claimable":false,"name":"Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.","description":"Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare adverse events have been described. Here we describe a unique and severe adverse event of VST therapy in an infant with severe combined immunodeficiency, who receives, as part of a clinical trial (NCT03475212), third party VSTs for treating cytomegalovirus viremia following bone marrow transplantation. At one-month post-VST infusion, rejection of graft and reversal of chimerism is observed, as is an expansion of T cells exclusively from the VST donor. Single-cell gene expression and T cell receptor profiling demonstrate a narrow repertoire of predominantly activated CD4<sup>+</sup>","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-07-16T12:04:38.36Z","creation":"2025-04-19T10:15:13.036Z"},"accession":"S-EPMC10980733","cross_references":{"pubmed":["38553461"],"doi":["10.1038/s41467-024-47056-3"]}}